Back to search
FDAFDA · Food and drugs·Recall number Z-1466-2020

RayStation/RayPlan 8B Service Pack 2, Build Number 8.1.2.5, stand-alone software treatment planning system

Published March 18, 2020 · Recall initiated: February 20, 2020

Summary

FDA records medical device Class II recall Z-1466-2020, published March 18, 2020 and initiated February 20, 2020. Recalling firm: RAYSEARCH LABORATORIES AB; Status: Terminated; Reported quantity: 1 system in the U.S.; Lot: UDI 07350002010235. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

There is a potential for erroneous propagation of the current tabletop positions when applying pitch or roll correction. Even though pitch and roll correction is never propagated, non-zero pitch or roll causes the lateral, longitudinal and vertical values propagated to be incorrect.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RAYSEARCH LABORATORIES AB
Distributor
The products were distributed to the following US states: TN
Lot
UDI 07350002010235
Risk classification
Class II
Area (FDA)
device
Country
Sweden

Related recalls

Questions about this recall

Was RayStation/RayPlan 8B Service Pack 2, Build Number 8.1.2.5, stand-alone software treatment planning system recalled?

Yes. FDA published recall Z-1466-2020 on March 18, 2020. Reported hazard: There is a potential for erroneous propagation of the current tabletop positions when applying pitch or roll correction. Even though pitch and roll correction is never propagated, non-zero pitch or roll causes the lateral, longitudinal and vertical values propagated to be incorrect.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail